{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:00:11Z","timestamp":1787317211442,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s10741-021-10077-x","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T04:04:46Z","timestamp":1611115486000},"page":"741-753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction"],"prefix":"10.1007","volume":"27","author":[{"given":"Stephen J.","family":"Greene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bernauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"issue":"10159","key":"10077_CR1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"GBD","year":"2017","unstructured":"GBD (2017) Disease and injury incidence and prevalence collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1789\u20131858. https:\/\/doi.org\/10.1016\/S0140-6736(18)32279-7","journal-title":"Lancet"},{"issue":"1","key":"10077_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","volume":"3","author":"G Savarese","year":"2017","unstructured":"Savarese G, Lund LH (2017) Global public health burden of heart failure. Card Fail Rev 3(1):7\u201311. https:\/\/doi.org\/10.15420\/cfr.2016:25:2","journal-title":"Card Fail Rev"},{"issue":"6","key":"10077_CR3","doi-asserted-by":"publisher","first-page":"e0218983","DOI":"10.1371\/journal.pone.0218983","volume":"14","author":"X Chen","year":"2019","unstructured":"Chen X, Xin Y, Hu W, Zhao Y, Zhang Z, Zhou Y (2019) Quality of life and outcomes in heart failure patients with ejection fractions in different ranges. PLoS ONE 14(6):e0218983. https:\/\/doi.org\/10.1371\/journal.pone.0218983","journal-title":"PLoS ONE"},{"issue":"3","key":"10077_CR4","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijcard.2013.12.028","volume":"171","author":"C Cook","year":"2014","unstructured":"Cook C, Cole G, Asaria P, Jabbour R, Francis DP (2014) The annual global economic burden of heart failure. Int J Cardiol 171(3):368\u2013376. https:\/\/doi.org\/10.1016\/j.ijcard.2013.12.028","journal-title":"Int J Cardiol"},{"key":"10077_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ahj.2017.06.016","volume":"191","author":"N Luo","year":"2017","unstructured":"Luo N, Teng TK, Tay WT, Anand IS, Kraus WE, Liew HB, Ling LH, O\u2019Connor CM, Pina IL, Richards AM, Shimizu W, Whellan DJ, Yap J, Lam CSP, Mentz RJ, Asian HF, investigators H-A, (2017) Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure. Am Heart J 191:75\u201381. https:\/\/doi.org\/10.1016\/j.ahj.2017.06.016","journal-title":"Am Heart J"},{"issue":"1","key":"10077_CR6","doi-asserted-by":"publisher","first-page":"e003529","DOI":"10.1161\/circheartfailure.116.003529","volume":"10","author":"H Burnett","year":"2017","unstructured":"Burnett H, Earley A, Voors AA, Senni M, McMurray JJ, Deschaseaux C, Cope S (2017) Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circulation Heart failure 10(1):e003529. https:\/\/doi.org\/10.1161\/circheartfailure.116.003529","journal-title":"Circulation Heart failure"},{"issue":"8","key":"10077_CR7","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonz\u00e1lez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Filippatos G, McMurray JJV, Aboyans V, Achenbach S, Agewall S, Al-Attar N, Atherton JJ, Bauersachs J, Camm AJ, Carerj S, Ceconi C, Coca A, Elliott P, Erol \u00c7, Ezekowitz J, Fern\u00e1ndez-Golf\u00edn C, Fitzsimons D, Guazzi M, Guenoun M, Hasenfuss G, Hindricks G, Hoes AW, Iung B, Jaarsma T, Kirchhof P, Knuuti J, Kolh P, Konstantinides S, Lainscak M, Lancellotti P, Lip GYH, Maisano F, Mueller C, Petrie MC, Piepoli MF, Priori SG, Torbicki A, Tsutsui H, van Veldhuisen DJ, Windecker S, Yancy C, Zamorano JL (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891\u2013975. https:\/\/doi.org\/10.1002\/ejhf.592","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10077_CR8","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","volume":"23","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail 23(8):628\u2013651. https:\/\/doi.org\/10.1016\/j.cardfail.2017.04.014","journal-title":"J Card Fail"},{"issue":"16","key":"10077_CR9","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8776","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, College A, of Cardiology Foundation, American Heart Association Task Force on Practice G, (2013) 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation 128(16):e240-327. https:\/\/doi.org\/10.1161\/CIR.0b013e31829e8776","journal-title":"Circulation"},{"issue":"20","key":"10077_CR10","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O\u2019Connor CM, Group VS (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382(20):1883\u20131893. https:\/\/doi.org\/10.1056\/NEJMoa1915928","journal-title":"N Engl J Med"},{"issue":"21","key":"10077_CR11","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM, Committees DHT, Investigators, (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"issue":"15","key":"10077_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Bohm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, Investigators EM-RT (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"10077_CR13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025797","author":"JR Teerlink","year":"2020","unstructured":"Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sorensen T, Bohm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlstrom U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O\u2019Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE, Investigators GH (2020) Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2025797","journal-title":"N Engl J Med"},{"issue":"12","key":"10077_CR14","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jcma.2017.04.011","volume":"80","author":"HY Chang","year":"2017","unstructured":"Chang HY, Wang CC, Wei J, Chang CY, Chuang YC, Huang CL, Chong E, Lin JL, Mar GY, Chan KC, Kuo JY, Wang JH, Chen ZC, Tseng WK, Cherng WJ, Yin WH (2017) Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: results from TSOC-HFrEF registry. J Chin Med Assoc 80(12):750\u2013757. https:\/\/doi.org\/10.1016\/j.jcma.2017.04.011","journal-title":"J Chin Med Assoc"},{"issue":"6","key":"10077_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s10741-016-9575-2","volume":"21","author":"KL Chin","year":"2016","unstructured":"Chin KL, Skiba M, Tonkin A, Reid CM, Liew D, Krum H, Hopper I (2016) The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice. Heart Fail Rev 21(6):675\u2013697. https:\/\/doi.org\/10.1007\/s10741-016-9575-2","journal-title":"Heart Fail Rev"},{"issue":"3","key":"10077_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jamacardio.2017.5250","volume":"3","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Mentz RJ, Felker GM (2018) Outpatient worsening heart failure as a target for therapy: a review. JAMA Cardiol 3(3):252\u2013259. https:\/\/doi.org\/10.1001\/jamacardio.2017.5250","journal-title":"JAMA Cardiol"},{"issue":"11","key":"10077_CR17","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1002\/ejhf.887","volume":"19","author":"M Komajda","year":"2017","unstructured":"Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS (2017) Physicians\u2019 guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 19(11):1414\u20131423. https:\/\/doi.org\/10.1002\/ejhf.887","journal-title":"Eur J Heart Fail"},{"issue":"19","key":"10077_CR18","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.jacc.2019.03.464","volume":"73","author":"B Bozkurt","year":"2019","unstructured":"Bozkurt B (2019) Reasons for lack of improvement in treatment with evidence-based therapies in heart failure. J Am Coll Cardiol 73(19):2384\u20132387. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.464","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10077_CR19","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100. https:\/\/doi.org\/10.1371\/journal.pmed.1000100","journal-title":"PLoS Med"},{"issue":"10","key":"10077_CR20","doi-asserted-by":"publisher","first-page":"933 989","DOI":"10.1016\/j.ejheart.2008.08.005","volume":"10","author":"K Dickstein","year":"2008","unstructured":"Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10(10):933 989. https:\/\/doi.org\/10.1016\/j.ejheart.2008.08.005","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"10077_CR21","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33(14):1787\u20131847. https:\/\/doi.org\/10.1093\/eurheartj\/ehs104","journal-title":"Eur Heart J"},{"issue":"3","key":"10077_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/ehf2.12258","volume":"5","author":"P Martens","year":"2018","unstructured":"Martens P, Beli\u00ebn H, Dupont M, Mullens W (2018) Insights into implementation of sacubitril\/valsartan into clinical practice. ESC heart failure 5(3):275\u2013283. https:\/\/doi.org\/10.1002\/ehf2.12258","journal-title":"ESC heart failure"},{"issue":"15","key":"10077_CR23","doi-asserted-by":"publisher","first-page":"e008789","DOI":"10.1161\/JAHA.118.008789","volume":"7","author":"LG Gilstrap","year":"2018","unstructured":"Gilstrap LG, Stevenson LW, Small R, Parambi R, Hamershock R, Greenberg J, Carr C, Ghazinouri R, Rathman L, Han E, Mehra MR, Desai AS (2018) Reasons for guideline nonadherence at heart failure discharge. J Am Heart Assoc 7(15):e008789. https:\/\/doi.org\/10.1161\/JAHA.118.008789","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10077_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5830\/CVJA-2019-001","volume":"30","author":"J Bolon","year":"2019","unstructured":"Bolon J, McCutcheon K, Klug E, Smith D, Manga P (2019) Beta-blocker target dosing and tolerability in a dedicated heart failure clinic in Johannesburg. Cardiovascular journal of Africa 30(2):103\u2013107. https:\/\/doi.org\/10.5830\/CVJA-2019-001","journal-title":"Cardiovascular journal of Africa"},{"issue":"4","key":"10077_CR25","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/ehf2.12452","volume":"6","author":"B Atallah","year":"2019","unstructured":"Atallah B, Sadik ZG, Hisham M, Kalagieh O, Hamour I, Gabra G, El Banna M, Soliman M, Cherfan A, Bader F (2019) A per-protocol initiation of sacubitril\/valsartan in an advanced heart failure disease management programme in the Middle East Gulf Region. ESC Heart Fail 6(4):758\u2013763. https:\/\/doi.org\/10.1002\/ehf2.12452","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10077_CR26","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.ijcard.2015.03.428","volume":"187","author":"SB Barywani","year":"2015","unstructured":"Barywani SB, Ergatoudes C, Schaufelberger M, Petzold M, Fu MLX (2015) Does the target dose of neurohormonal blockade matter for outcome in systolic heart failure in octogenarians? Int J Cardiol 187(1):666\u2013672. https:\/\/doi.org\/10.1016\/j.ijcard.2015.03.428","journal-title":"Int J Cardiol"},{"issue":"2","key":"10077_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/phar.1701","volume":"36","author":"AP Bress","year":"2016","unstructured":"Bress AP, King JB, Brixner D, Kielhorn A, Patel HK, Maya J, Lee VC, Biskupiak J, Munger M (2016) Pharmacotherapy treatment patterns, outcomes, and health resource utilization among patients with heart failure with reduced ejection fraction at a U.S. Academic Medical Center. Pharmacotherapy 36(2):174\u2013186. https:\/\/doi.org\/10.1002\/phar.1701","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10077_CR28","doi-asserted-by":"publisher","first-page":"e1002805","DOI":"10.1371\/journal.pmed.1002805","volume":"16","author":"N Conrad","year":"2019","unstructured":"Conrad N, Judge A, Canoy D, Tran J, O\u2019Donnell J, Nazarzadeh M, Salimi-Khorshidi G, Hobbs FDR, Cleland JG, McMurray JJV, Rahimi K (2019) Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: a cohort study of 93,000 UK patients. PLoS medicine 16(5):e1002805. https:\/\/doi.org\/10.1371\/journal.pmed.1002805","journal-title":"PLoS medicine"},{"issue":"11","key":"10077_CR29","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s00392-018-1277-4","volume":"107","author":"A Corletto","year":"2018","unstructured":"Corletto A, Fr\u00f6hlich H, T\u00e4ger T, Hochadel M, Zahn R, Kilkowski C, Winkler R, Senges J, Katus HA, Frankenstein L (2018) Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy. Clin Res Cardiol 107(11):1040\u20131049. https:\/\/doi.org\/10.1007\/s00392-018-1277-4","journal-title":"Clin Res Cardiol"},{"issue":"6","key":"10077_CR30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s12325-018-0710-4","volume":"35","author":"DD Antol","year":"2018","unstructured":"Antol DD, Casebeer AW, DeClue RW, Stemkowski S, Russo PA (2018) An Early view of real-world patient response to sacubitril\/valsartan: a retrospective study of patients with heart failure with reduced ejection fraction. Advances in Therapy 35(6):785\u2013795. https:\/\/doi.org\/10.1007\/s12325-018-0710-4","journal-title":"Advances in Therapy"},{"issue":"8","key":"10077_CR31","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jacc.2018.11.049","volume":"73","author":"J Butler","year":"2019","unstructured":"Butler J, Yang M, Manzi MA, Hess GP, Patel MJ, Rhodes T, Givertz MM (2019) Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol 73(8):935\u2013944. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.049","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10077_CR32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/FJC.0000000000000643","volume":"73","author":"AX Du","year":"2019","unstructured":"Du AX, Westerhout CM, McAlister FA, Shanks M, Oudit GY, Paterson DI, Hanninen M, Thomas J, Ezekowitz JA (2019) Titration and tolerability of sacubitril\/valsartan for patients with heart failure in clinical practice. J Cardiovasc Pharmacol 73(3):149\u2013154. https:\/\/doi.org\/10.1097\/FJC.0000000000000643","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"10077_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10741-019-09777-2","volume":"24","author":"WJ Kruik-Kolloffel","year":"2019","unstructured":"Kruik-Kolloffel WJ, Linssen GCM, Kruik HJ, Movig KLL, Heintjes EM, van der Palen J (2019) Effects of European Society of Cardiology guidelines on medication profiles after hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015. Heart Fail Rev 24(4):499\u2013510. https:\/\/doi.org\/10.1007\/s10741-019-09777-2","journal-title":"Heart Fail Rev"},{"issue":"8","key":"10077_CR34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cardfail.2017.03.001","volume":"23","author":"P Martens","year":"2017","unstructured":"Martens P, Verbrugge FH, Nijst P, Bertrand PB, Dupont M, Tang WH, Mullens W (2017) Feasibility and association of neurohumoral blocker up-titration after cardiac resynchronization therapy. J Cardiac Fail 23(8):597\u2013605. https:\/\/doi.org\/10.1016\/j.cardfail.2017.03.001","journal-title":"J Cardiac Fail"},{"issue":"2","key":"10077_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40256-018-0264-5","volume":"18","author":"EK Pogge","year":"2018","unstructured":"Pogge EK, Davis LE (2018) Evaluating the safety and tolerability of sacubitril\/valsartan for HFrEF managed within a pharmacist clinic. American journal of cardiovascular drugs\u202f: drugs, devices, and other interventions 18(2):143\u2013151. https:\/\/doi.org\/10.1007\/s40256-018-0264-5","journal-title":"American journal of cardiovascular drugs : drugs, devices, and other interventions"},{"issue":"5","key":"10077_CR36","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ejhf.1465","volume":"21","author":"R Wachter","year":"2019","unstructured":"Wachter R, Fonseca AF, Balas B, Kap E, Engelhard J, Schlienger R, Klebs S, Wirta SB, Kostev K (2019) Real-world treatment patterns of sacubitril\/valsartan: a longitudinal cohort study in Germany. Eur J Heart Fail 21(5):588\u2013597. https:\/\/doi.org\/10.1002\/ejhf.1465","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10077_CR37","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/ejhf.900","volume":"19","author":"JP Ferreira","year":"2017","unstructured":"Ferreira JP, Rossignol P, Machu J-L, Sharma A, Girerd N, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Lang CC, ter Maaten JM, Metra M, Ng L, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Voors A, Zannad F (2017) Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. Eur J Heart Fail 19(10):1284\u20131293. https:\/\/doi.org\/10.1002\/ejhf.900","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10077_CR38","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.rec.2015.03.008","volume":"68","author":"MG Crespo-Leiro","year":"2015","unstructured":"Crespo-Leiro MG, Segovia-Cubero J, Gonz\u00e1lez-Costello J, Bayes-Genis A, L\u00f3pez-Fern\u00e1ndez S, Roig E, Sanz-Julve M, Fern\u00e1ndez-Vivancos C, de Mora-Mart\u00edn M, Garc\u00eda-Pinilla JM, Varela-Rom\u00e1n A, Almenar-Bonet L, Lara-Padr\u00f3n A, de la Fuente-Gal\u00e1n L, Delgado-Jim\u00e9nez J (2015) Adherence to the ESC heart failure treatment guidelines in Spain: ESC Heart Failure Long-term Registry. Rev Esp Cardiol (English ed) 68(9):785\u2013793. https:\/\/doi.org\/10.1016\/j.rec.2015.03.008","journal-title":"Rev Esp Cardiol (English ed)"},{"issue":"4","key":"10077_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, Hill CL, McCague K, Mi X, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Fonarow GC (2018) Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry. J Am Coll Cardiol 72(4):351\u2013366. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.070","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10077_CR40","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","volume":"73","author":"SJ Greene","year":"2019","unstructured":"Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, Duffy CI, Hill CL, McCague K, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Butler J (2019) Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 73(19):2365\u20132383. https:\/\/doi.org\/10.1016\/j.jacc.2019.02.015","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10077_CR41","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ejhf.1459","volume":"21","author":"M Komajda","year":"2019","unstructured":"Komajda M, Schope J, Wagenpfeil S, Tavazzi L, Bohm M, Ponikowski P, Anker SD, Filippatos GS, Cowie MR, Investigators Q (2019) Physicians\u2019 guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 21(7):921\u2013929. https:\/\/doi.org\/10.1002\/ejhf.1459","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10077_CR42","doi-asserted-by":"publisher","first-page":"352","DOI":"10.5830\/CVJA-2018-039","volume":"29","author":"\u00c9 Laflamme","year":"2018","unstructured":"Laflamme \u00c9, Vachon A, Gilbert S, Boisvert J, Leclerc V, Bernier M, Voisine P, S\u00e9n\u00e9chal M, Bergeron S (2018) Usefulness of a titration algorithm for de novo users of sacubitril\/valsartan in a tertiary centre heart failure clinic. Cardiovascular Journal of Africa 29(6):352\u2013356. https:\/\/doi.org\/10.5830\/CVJA-2018-039","journal-title":"Cardiovascular Journal of Africa"},{"issue":"24","key":"10077_CR43","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","volume":"38","author":"W Ouwerkerk","year":"2017","unstructured":"Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, Van Der Harst P, Hillege HL, Lang CC, Ter Maaten JM, Ng LL, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Metra M, Zwinderman AH (2017) Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 38(24):1883\u20131890. https:\/\/doi.org\/10.1093\/eurheartj\/ehx026","journal-title":"Eur Heart J"},{"issue":"9","key":"10077_CR44","doi-asserted-by":"publisher","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","volume":"6","author":"T-HK Teng","year":"2018","unstructured":"Teng T-HK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, Wander GS, Yap JJ, MacDonald MR, Xu CF, Chia YM, Shimizu W, Richards AM, Voors A, Lam CS (2018) Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. The Lancet Global health 6(9):e1008\u2013e1018. https:\/\/doi.org\/10.1016\/S2214-109X(18)30306-1","journal-title":"The Lancet Global health"},{"issue":"10","key":"10077_CR45","doi-asserted-by":"publisher","first-page":"657","DOI":"10.20452\/pamw.4083","volume":"127","author":"G Opolski","year":"2017","unstructured":"Opolski G, Oziera\u0144ski K, Lelonek M, Balsam P, Wilkins A, Ponikowski P, Polish Qualify Investigators (2017) Adherence to the guidelines on the management of systolic heart failure in ambulatory care in Poland. Data from the international QUALIFY survey. Pol Arch Intern Med 127(10):657\u2013665. https:\/\/doi.org\/10.20452\/pamw.4083","journal-title":"Pol Arch Intern Med"},{"issue":"2","key":"10077_CR46","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/FJC.0000000000000641","volume":"73","author":"L Vicent","year":"2019","unstructured":"Vicent L, Esteban-Fern\u00e1ndez A, G\u00f3mez-Bueno M, De-Juan J, Di\u00e9z-Villanueva P, Iniesta \u00c1M, Ayesta A, Gonz\u00e1lez-Sald\u00edvar H, Rojas-Gonz\u00e1lez A, Bover-Freire R, Iglesias D, Garci\u00e1-Aguado M, Perea-Egido JA, Mart\u00ednez-Sell\u00e9s M (2019) Sacubitril\/valsartan in daily clinical practice: data from a prospective registry. J Cardiovasc Pharmacol 73(2):118\u2013124. https:\/\/doi.org\/10.1097\/FJC.0000000000000641","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"10077_CR47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13104-017-2820-5","volume":"11","author":"TM Atey","year":"2018","unstructured":"Atey TM, Teklay T, Asgedom SW, Mezgebe HB, Teklay G, Kahssay M (2018) Treatment optimization of angiotensin converting enzyme inhibitors and associated factors in Ayder Comprehensive Specialized Hospital: a cross-sectional study. BMC Res Notes 11(1):209. https:\/\/doi.org\/10.1186\/s13104-017-2820-5","journal-title":"BMC Res Notes"},{"issue":"1","key":"10077_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","volume":"7","author":"HP Brunner-La Rocca","year":"2019","unstructured":"Brunner-La Rocca HP, Linssen GC, Smeele FJ, van Drimmelen AA, Schaafsma HJ, Westendorp PH, Rademaker PC, van de Kamp HJ, Hoes AW, Brugts JJ (2019) Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF Registry. JACC: Heart Fail 7(1):13\u201321. https:\/\/doi.org\/10.1016\/j.jchf.2018.10.010","journal-title":"JACC: Heart Fail"},{"issue":"1","key":"10077_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10557-017-6768-4","volume":"32","author":"KL Chin","year":"2018","unstructured":"Chin KL, Skiba M, Reid CM, Tonkin A, Hopper I, Mariani JA, Liew D (2018) Mind the gap: mismatches between clinicians and patients in heart failure medication management. Cardiovasc Drugs Ther 32(1):37\u201346. https:\/\/doi.org\/10.1007\/s10557-017-6768-4","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"10077_CR50","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3109\/13561820.2015.1027334","volume":"29","author":"ME Crissinger","year":"2015","unstructured":"Crissinger ME, Marchionda KM, Dunlap ME (2015) Adherence to clinical guidelines in heart failure (HF) outpatients: impact of an interprofessional HF team on evidence-based medication use. J Interprof Care 29(5):483\u2013487. https:\/\/doi.org\/10.3109\/13561820.2015.1027334","journal-title":"J Interprof Care"},{"key":"10077_CR51","doi-asserted-by":"publisher","first-page":"9463872","DOI":"10.1155\/2019\/9463872","volume":"2019","author":"YL Niriayo","year":"2019","unstructured":"Niriayo YL, Kumela K, Gidey K, Angamo MT (2019) Utilization and dose optimization of angiotensin-converting enzyme inhibitors among heart failure patients in Southwest Ethiopia. Biomed Res Int 2019:9463872. https:\/\/doi.org\/10.1155\/2019\/9463872","journal-title":"Biomed Res Int"},{"issue":"7","key":"10077_CR52","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/pds.4430","volume":"27","author":"S El Hadidi","year":"2018","unstructured":"El Hadidi S, Darweesh E, Byrne S, Bermingham M (2018) A tool for assessment of heart failure prescribing quality: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 27(7):685\u2013694. https:\/\/doi.org\/10.1002\/pds.4430","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10077_CR53","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00392-015-0939-8","volume":"105","author":"MN Hirt","year":"2016","unstructured":"Hirt MN, Muttardi A, Helms TM, van den Bussche H, Eschenhagen T (2016) General practitioners\u2019 adherence to chronic heart failure guidelines regarding medication: the GP-HF study. Clin Res Cardiol 105(5):441\u2013450. https:\/\/doi.org\/10.1007\/s00392-015-0939-8","journal-title":"Clin Res Cardiol"},{"issue":"3","key":"10077_CR54","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10557-019-06858-0","volume":"33","author":"C Moliner-Abos","year":"2019","unstructured":"Moliner-Abos C, Rivas-Lasarte M, Pamies Besora J, Fluvia-Brugues P, Sole-Gonzalez E, Mirabet S, Lopez Lopez L, Brossa V, Pirla MJ, Mesado N, Alvarez-Garcia J, Roig E (2019) Sacubitril\/valsartan in real-life practice: experience in patients with advanced heart failure and systematic review. Cardiovasc Drugs Ther 33(3):307\u2013314. https:\/\/doi.org\/10.1007\/s10557-019-06858-0","journal-title":"Cardiovasc Drugs Ther"},{"key":"10077_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1857.10.1002\/ejhf.1857","author":"M Packer","year":"2020","unstructured":"Packer M, Metra M (2020) Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction. European journal of heart failure:doi. https:\/\/doi.org\/10.1002\/ejhf.1857.10.1002\/ejhf.1857","journal-title":"European journal of heart failure:doi"},{"issue":"5","key":"10077_CR56","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"SOLVD Investigators","year":"1991","unstructured":"Investigators SOLVD, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325(5):293\u2013302. https:\/\/doi.org\/10.1056\/NEJM199108013250501","journal-title":"N Engl J Med"},{"issue":"1","key":"10077_CR57","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, Group E-HS","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, Group E-HS (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"issue":"22","key":"10077_CR58","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","volume":"344","author":"Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival Study G","year":"2001","unstructured":"Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival Study G (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344(22):1651\u20131658. https:\/\/doi.org\/10.1056\/NEJM200105313442201","journal-title":"N Engl J Med"},{"issue":"12","key":"10077_CR59","doi-asserted-by":"publisher","first-page":"e009237","DOI":"10.1161\/JAHA.118.009237","volume":"7","author":"AD DeVore","year":"2018","unstructured":"DeVore AD, Mi X, Thomas L, Sharma PP, Albert NM, Butler J, Hernandez AF, Patterson JH, Spertus JA, Williams FB, Duffy CI, McCague K, Fonarow GC (2018) Characteristics and treatments of patients enrolled in the CHAMP-HF Registry compared with patients enrolled in the PARADIGM-HF Trial. J Am Heart Assoc 7(12):e009237. https:\/\/doi.org\/10.1161\/JAHA.118.009237","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10077_CR60","doi-asserted-by":"publisher","first-page":"e006645","DOI":"10.1161\/CIRCHEARTFAILURE.119.006645","volume":"13","author":"M Fudim","year":"2020","unstructured":"Fudim M, Sayeed S, Xu H, Matsouaka RA, Heidenreich PA, Velazquez EJ, Yancy CW, Fonarow GC, Hernandez AF, DeVore AD (2020) Representativeness of the PIONEER-HF clinical trial population in patients hospitalized with heart failure and reduced ejection fraction. Circulation Heart failure 13(4):e006645. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.119.006645","journal-title":"Circulation Heart failure"},{"issue":"3","key":"10077_CR61","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jacc.2012.03.023","volume":"60","author":"M Fiuzat","year":"2012","unstructured":"Fiuzat M, Wojdyla D, Kitzman D, Fleg J, Keteyian SJ, Kraus WE, Pina IL, Whellan D, O\u2019Connor CM (2012) Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. J Am Coll Cardiol 60(3):208\u2013215. https:\/\/doi.org\/10.1016\/j.jacc.2012.03.023","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10077_CR62","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jchf.2015.09.002","volume":"4","author":"M Fiuzat","year":"2016","unstructured":"Fiuzat M, Wojdyla D, Pina I, Adams K, Whellan D, O\u2019Connor CM (2016) Heart rate or beta-blocker dose? association with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION Trial. JACC Heart failure 4(2):109\u2013115. https:\/\/doi.org\/10.1016\/j.jchf.2015.09.002","journal-title":"JACC Heart failure"},{"key":"10077_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.04.019","author":"M Jarjour","year":"2020","unstructured":"Jarjour M, Henri C, de Denus S, Fortier A, Bouabdallaoui N, Nigam A, O\u2019Meara E, Ahnadi C, White M, Garceau P, Racine N, Parent MC, Liszkowski M, Giraldeau G, Rouleau JL, Ducharme A (2020) Care gaps in adherence to heart failure guidelines: clinical inertia or physiological limitations? JACC Heart failure. https:\/\/doi.org\/10.1016\/j.jchf.2020.04.019","journal-title":"JACC Heart failure"},{"issue":"13","key":"10077_CR64","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.jacc.2019.08.014","volume":"74","author":"DL Dixon","year":"2019","unstructured":"Dixon DL, Sharma G, Sandesara PB, Yang E, Braun LT, Mensah GA, Sperling LS, Deedwania PC, Virani SS (2019) Therapeutic inertia in cardiovascular disease prevention: time to move the bar. J Am Coll Cardiol 74(13):1728\u20131731. https:\/\/doi.org\/10.1016\/j.jacc.2019.08.014","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10077_CR65","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/j.jacc.2011.02.020","volume":"57","author":"NM Hawkins","year":"2011","unstructured":"Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wikstrand J, McMurray JJ (2011) Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. J Am Coll Cardiol 57(21):2127\u20132138. https:\/\/doi.org\/10.1016\/j.jacc.2011.02.020","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10077_CR66","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/s0954-6111(03)00168-9","volume":"97","author":"SR Salpeter","year":"2003","unstructured":"Salpeter SR, Ormiston TM, Salpeter EE, Poole PJ, Cates CJ (2003) Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 97(10):1094\u20131101. https:\/\/doi.org\/10.1016\/s0954-6111(03)00168-9","journal-title":"Respir Med"},{"key":"10077_CR67","doi-asserted-by":"publisher","unstructured":"Salpeter S, Ormiston T, Salpeter E (2005) Cardioselective beta-blockers for chronic obstructive pulmonary disease. The Cochrane database of systematic reviews (4):CD003566. https:\/\/doi.org\/10.1002\/14651858.CD003566.pub2","DOI":"10.1002\/14651858.CD003566.pub2"},{"issue":"10","key":"10077_CR68","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jchf.2019.05.009","volume":"7","author":"M Canepa","year":"2019","unstructured":"Canepa M, Franssen FME, Olschewski H, Lainscak M, Bohm M, Tavazzi L, Rosenkranz S (2019) Diagnostic and therapeutic gaps in patients with heart failure and chronic obstructive pulmonary disease. JACC Heart failure 7(10):823\u2013833. https:\/\/doi.org\/10.1016\/j.jchf.2019.05.009","journal-title":"JACC Heart failure"},{"key":"10077_CR69","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.4987","author":"MD Samsky","year":"2019","unstructured":"Samsky MD, Lin L, Greene SJ, Lippmann SJ, Peterson PN, Heidenreich PA, Laskey WK, Yancy CW, Greiner MA, Hardy NC, Kavati A, Park S, Mentz RJ, Fonarow GC, O\u2019Brien EC (2019) Patient perceptions and familiarity with medical therapy for heart failure. JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2019.4987","journal-title":"JAMA Cardiol"},{"issue":"7 Suppl 1","key":"10077_CR70","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/01.NPR.0000520610.88962.03","volume":"42","author":"BT Davidson","year":"2017","unstructured":"Davidson BT, Allison TL (2017) Improving heart failure patient outcomes utilizing guideline-directed therapy. Nurse Pract 42(7 Suppl 1):2\u201314. https:\/\/doi.org\/10.1097\/01.NPR.0000520610.88962.03","journal-title":"Nurse Pract"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-021-10077-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-021-10077-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-021-10077-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T19:05:46Z","timestamp":1650654346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-021-10077-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10077"],"URL":"https:\/\/doi.org\/10.1007\/s10741-021-10077-x","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,20]]},"assertion":[{"value":"6 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Stephen J. Greene has received a Heart Failure Society of America\/ Emergency Medicine Foundation Acute Heart Failure Young Investigator Award funded by Novartis; has received research support from the American Heart Association, Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, and Novartis; has served on advisory boards for Amgen and Cytokinetics; and serves as a consultant for Amgen and Merck. Xi Tan and Mei Yang are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and stockholders of Merck & Co., Inc., Kenilworth, NJ, USA. Yu-Chen Yeh, Mark Bernauer, and Omer Zaidi are employees of Pharmerit, which received research support from Merck & Co., Inc. to conduct the study. Javed Butler serves as a consultant to Abbott, Array, Amgen, Applied Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, CVRx, Eli Lilly,\u00a0G3 Pharma, Impulse Dynamics, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Sequana Medical, V-Wave Limited, and Vifor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}